Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMS-D001 in moderate to severe atopic dermatitis
NCT07465120Phase 2Not yet recruiting
- Sponsor
- Dermavant Sciences
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CMS-D001 in atopic dermatitis (AD), sponsored by Dermavant Sciences. Primary endpoint: Eczema Area and Severity Index 75% improvement at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CMS-D001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07465120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465120.